CandidatesPreclinicalPhase 1Phase 2Phase 3reg. filiingmarketed
Tivozanib (RCC)
VEGFR 123 TKI
TIVO - 1
TIVO - 3
TiNivo
Tivozanib (HCC)
DEDUCTIVE
Ficlatuzumab
HGF MAb
SCCHN
Pancreatic
CyFi-2
AV-203
(CAN017)

ERBB3 MAb
Esophageal
Tivozanib
VEGFR 123 TKI
Non-Oncology
AV-380
GDF15 MAb
Cachexia
AV-353
Notch 3 MAb
Oncology
ongoing or completein planning
Tivozanib (RCC)
VEGFR 123 TKI
TIVO - 1 marketed
TIVO - 3 Phase 3
TiNivo Phase 2
Tivozanib (HCC)
DEDUCTIVE Phase 2
Ficlatuzumab
HGF MAb
SCCHN Phase 2
Pancreatic Phase 2
CyFi-2 Phase 2
AV-203
(CAN017)

ERBB3 MAb
Esophageal Preclinical
Tivozanib
VEGFR 123 TKI
Non-Oncology Preclinical
AV-380
GDF15 MAb
Cachexia Preclinical
AV-353
Notch 3 MAb
Oncology Preclinical

AVEO Pharmaceuticals is a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs. The Company’s lead candidate is tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, which AVEO is seeking to develop and commercialize in North America as a treatment for renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and other cancers. Tivozanib (FOTIVDA®) is approved by the European Commission for the treatment of adult patients with advanced RCC in the European Union plus Norway, New Zealand and Iceland. AVEO is leveraging or seeks to leverage partnerships to develop and commercialize its pipeline of products and product candidates, including tivozanib in oncology and other indications in various geographies, and ficlatuzumab (HGF MAb) in head and neck cancer, pancreatic cancer and acute myeloid leukemia. AVEO’s earlier-stage pipeline includes AV-203 (anti-ErbB3 MAb), AV-380 (GDF15 MAb) and AV-353 (Notch 3 MAb) drug candidates being developed for various oncology indications.

Focused on Patients. Driven by Science.